Nanopath develops molecular diagnostic technology for women's health, focusing on deep technological breakthroughs that have the potential to change the molecular diagnostic paradigm.

Nanopath

Nanopath is a molecular diagnostics company disrupting traditional testing methodologies. We aim to improve the health of women by providing granular and clinically actionable information within a single office visit. 


National Science Foundation

Medtech Convergence Fund

Norwest Venture Partners

GingerBread Capital

Green D Ventures

Our founders Alison Burklund and Amogha Tadimety had a chance to chat with Carina about their journey founding and building Nanopath. 

A key focus of the conversation was Nanopath's amazing, mission-driven team - huge thank you to all of our amazing team members!

Alison Burklund recently participated in Women's Fund (An Alumni Ventures Fund) webinar discussing the unique challenges and lessons learned as a female CTO. Listen to Alison alongside her fellow CTO panelists Maria Telleria (Canvas) and Leila Deravi (Seaspire Skincare) in this important discussion.

Congratulations to the startup founders who received multiple term sheets from teams at VCIC Global Finals https://lnkd.in/eXjv-XuN

Tyler Morgan,  Upkid  |  Brad Moss, Enhanced Ai  
Erick McKesson, Rotera  |  Logan Meaux, Mallard Bay Outdoors
Vince Wong, ElectricFish  |  Jeffrey Bemowski, Clairways
Amogha Tadimety and Alison Burklund, Nanopath

UNC Kenan-Flagler Business School

Catch our co-founder Amogha Tadimety on this episode of Alumni Ventures' new podcast. She shares Nanopath's recent progress and plans for the future!

Our Senior VP of Assay Development, Matthew Black, and Senior Scientist, Cameron Crawford, represented Nanopath at Precision Med TRI-CON this week. They shared key insights about Nanopath’s impact in the point-of-care space and results from our partnership with Brigham and Women’s Hospital!

Please join us in welcoming the newest additions to the Nanopath team; Fulya Ekiz Kanik and Henry Hwang! More detail about their exciting backgrounds below: 

Fulya Ekiz Kanik holds degrees in chemistry (B.S., Middle East Technical University, Turkey), biotechnology (M.S., Middle East Technical University, Turkey), and biomedical engineering (M.S. UMass Lowell), and most recently earned her Ph.D. from Boston University. Her dissertation focused on innovative molecular diagnostic technologies, specializing in microRNA, rare mutation, and infectious disease detection. Dr. Kanik has expertise in surface modification for molecular assays and optical systems, and holds over 30 publications and 2 book chapters.

Henry Hanjun Hwang is a multi-disciplinary scientist and engineer with over a decade of experience in the biotechnology field. He earned his PhD from the University of California, San Diego, where he worked to integrate microfluidics, 3D printing, and tissue engineering to advance microphysiological systems applications. Dr. Hwang enjoys the pursuit of translating novel ideas into practical engineering solutions with a focus on scalable innovation.

COM:NANOPATHDX

Nanopath

Financials Not Available